September 17, 2014
London, United Kingdom
Following on the inventive step vs. obviousness webinar from earlier this year, this seminar will focus specifically on the chemical, biotechnology and pharmaceutical industries.
The requirements for inventive step in Europe and non-obviousness in the United States have many similarities but also some subtle differences. In most cases, you might expect similar results, but in some cases, you can end up with very different and unexpected outcomes. With global patenting strategies, companies often struggle to ensure consistency when prosecuting applications to grant in both jurisdictions. In this seminar, we shall look closely at obviousness at the U.S. Patent and Trademark Office (USPTO), inventive step at the European Patent Office (EPO), how they are both assessed and how objections can be overcome in the chemical, pharmaceutical, and biotechnology areas. Our panel will explore:
The panel will also discuss some of the techniques and strategies they have successfully implemented for patenting chemical and life sciences inventions, often in crowded art fields, including:
Admission is free, but space is limited. Please register by 12 September.
Moderator:
Anthony C. Tridico, Ph.D.
Speakers:
Bryan C. Diner
Erin M. Sommers, Ph.D.
Leythem A. Wall
Wednesday, 17 September 2014
12:30 - 13:00 - Registration
13:00 - 16:00 - Program
16:00 - 17:00 - Reception
Finnegan
16 Old Bailey
London EC4M 7EG
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.